遺伝性血管性浮腫治療薬の世界市場レポート 2025年

遺伝性血管性浮腫治療薬の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR19.7％で161億1,000万米ドルに成長します。予測期間の成長は、標的治療の進展、世界市場の拡大、遺伝子治療の開発、個別化医療の動向、研究開発と治療における共同研究に起因すると考えられます。予測期間の主な動向には、世界のアクセス構想、医療経済成果調査、早期介入戦略、小児HAE治療薬などがあります。

遺伝性血管性浮腫の有病率の増加が予想されることから、遺伝性血管性浮腫市場の今後の成長が期待されます。遺伝性血管性浮腫（HAE）は、皮膚や粘膜の再発性の激しい腫脹を特徴とするまれな遺伝性疾患であり、全世界で約50,000人に1人が罹患し、有病率は1,10,000～1,150,000人と推定されています。これらの症状は、米国だけでも年間15,000～30,000件の救急外来を受診しています。遺伝性血管性浮腫の発生率の増加は、遺伝性血管性浮腫市場の成長を促進する重要な要因です。

ヘルスケア支出の増加は、将来の遺伝性血管性浮腫治療薬市場の成長を促進すると予測されています。ヘルスケア支出とは、定義された地理的地域における特定の時間枠内で、ヘルスケア商品およびサービスのために割り当てられた財政投資を含む総資源を指します。ヘルスケア支出の増加は、遺伝性血管性浮腫の根本的な原因の解明と革新的な治療ソリューションの創出を目指した研究開発への投資を促進します。例えば、2022年12月、米国を拠点とする連邦機関であるメディケア＆メディケイドサービスセンターは、米国の医療費が4.1％増加し、2022年には4兆5,000億米ドルに達し、2021年の3.2％増を上回ったと報告しました。したがって、ヘルスケア支出の増加が遺伝性血管性浮腫治療薬市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界遺伝性血管性浮腫治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の遺伝性血管性浮腫治療薬市場：成長率分析
• 世界の遺伝性血管性浮腫治療薬市場の実績：規模と成長, 2019-2024
• 世界の遺伝性血管性浮腫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界遺伝性血管性浮腫治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の遺伝性血管性浮腫治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• C1エステラーゼ阻害剤
• 選択的ブラジキニンB2受容体拮抗薬
• カリクレイン阻害剤
• その他の薬物クラス
• 世界の遺伝性血管性浮腫治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 皮下
• オーラル
• 世界の遺伝性血管性浮腫治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の遺伝性血管性浮腫治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予防
• オンデマンド
• 世界の遺伝性血管性浮腫治療薬市場C1エステラーゼ阻害剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血漿由来
• 組み換え
• 世界の遺伝性血管性浮腫治療薬市場選択的ブラジキニンB2受容体拮抗薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• イカチバント
• 世界の遺伝性血管性浮腫治療薬市場カリクレイン阻害剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エカランチド
• ラナデルマブ
• 世界の遺伝性血管性浮腫治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 新たな治療法

第7章 地域別・国別分析

• 世界の遺伝性血管性浮腫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の遺伝性血管性浮腫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 遺伝性血管性浮腫治療薬市場：競合情勢
• 遺伝性血管性浮腫治療薬市場：企業プロファイル
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Pharming Healthcare Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Attune Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Adverum Biotechnologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Ionis Pharmaceuticals Inc.
• BioCryst Pharmaceuticals Inc.
• CSL Behring LLC
• KalVista Pharmaceutical Inc.
• CENTOGENE N.V.
• GlaxoSmithKline plc.
• Eli Lilly and Company
• Amgen Inc.
• AbbVie Inc.
• Incyte Corporation
• BioMarin Pharmaceutical Inc.
• Dyax Corp.
• Salix Pharmaceuticals Inc.
• Pharvaris N.V.
• Innovent Biologics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 遺伝性血管性浮腫治療薬市場2029：新たな機会を提供する国
• 遺伝性血管性浮腫治療薬市場2029：新たな機会を提供するセグメント
• 遺伝性血管性浮腫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hereditary angioedema (HAE) therapeutics pertain to the treatment of an autosomal dominant condition caused by a deficiency or malfunction of the C1-inhibitor protein. Symptoms of hereditary angioedema include angioedema-related upper airway, cutaneous, and/or gastrointestinal complaints.

The main drug classes of hereditary angioedema therapeutics include C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. C1 Esterase Inhibitor is a protein present in the fluid portion of blood that regulates the complement system's protein C1. These therapeutics are administered through intravenous, subcutaneous, and oral routes and are distributed via hospital pharmacies, retail pharmacies, and others. The application of hereditary angioedema therapeutics includes prophylaxis and on-demand treatment.

The hereditary angioedema therapeutics market research report is one of a series of new reports from The Business Research Company that provides hereditary angioedema therapeutics market statistics, including hereditary angioedema therapeutics industry global market size, regional shares, competitors with a hereditary angioedema therapeutics market share, detailed hereditary angioedema therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. This hereditary angioedema therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from$6.68 billion in 2024 to $7.84 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to improved diagnosis and awareness, treatment access expansion, research and development initiatives, patient advocacy and education, and regulatory approvals

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $16.11 billion in 2029 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, and collaboration in research and treatment. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, and pediatric HAE therapeutics.

The anticipated rise in the prevalence of hereditary angioedema is expected to drive the growth of the hereditary angioedema market in the future. Hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent severe swelling of the skin and mucous membranes, affects approximately 1 in every 50,000 individuals globally, with prevalence estimates ranging from 1,10,000 to 1,150,000. These episodes result in 15,000 to 30,000 emergency room visits annually in the US alone. The increasing incidence of hereditary angioedema is a significant factor propelling the growth of the hereditary angioedema market.

The rising healthcare expenditure is projected to enhance the growth of the hereditary angioedema therapeutics market in the future. Healthcare expenditure refers to the total resources, including financial investments, allocated for healthcare goods and services within a specific timeframe in a defined geographical area. Increased healthcare spending facilitates greater investment in research and development aimed at understanding the underlying causes of hereditary angioedema and creating innovative therapeutic solutions. For instance, in December 2022, the Centers for Medicare & Medicaid Services, a U.S.-based federal agency, reported that U.S. healthcare spending increased by 4.1% to reach $4.5 trillion in 2022, surpassing the 3.2% growth seen in 2021. Therefore, the rise in healthcare expenditure is propelling the growth of the hereditary angioedema therapeutics market.

A notable trend gaining traction in the hereditary angioedema therapeutics market is the emphasis on product innovation. Leading companies in this market are actively involved in the development of groundbreaking products, including ligand-conjugated (LICA) investigational antisense medicine and gene therapy, to reinforce their market position. In a significant development, Intellia Therapeutics, a clinical-stage biotechnology company based in the US, introduced an Investigational New Drug (IND) named NTLA-2002 in March 2023. This innovative therapy, approved by the United States Food and Drug Administration for hereditary angioedema treatment, allows the company's ongoing Phase 1/2 trial to incorporate the US into the global Phase 2 segment. NTLA-2002, a candidate for in vivo genome editing, aims to permanently lower plasma kallikrein protein activity and prevent hereditary angioedema attacks after a single dose of therapy through the inactivation of the target gene, kallikrein B1 (KLKB1).

Key companies in the hereditary angioedema (HAE) therapeutics market are focusing on developing innovative treatments, such as oral plasma kallikrein inhibitors, to improve patient management and provide effective on-demand solutions for alleviating HAE attacks. These oral medications work by inhibiting the enzyme plasma kallikrein, which helps manage and lessen the severity of hereditary angioedema episodes. For example, in September 2024, KalVista Pharmaceuticals, a U.S.-based biopharmaceutical company, received a new drug application approval from the U.S. Food and Drug Administration for Sebetralstat. This treatment aims to provide HAE patients with a more convenient, non-invasive alternative to intravenous or subcutaneous therapies. It addresses the increasing demand for rapid and effective oral treatments that can be administered immediately during an HAE attack, thereby enhancing overall patient outcomes and quality of life.

In February 2023, Takeda Pharmaceutical Company acquired Nimbus Lakshmi, Inc. from Nimbus Therapeutics, LLC. The acquisition, involving an undisclosed amount, enhances Takeda's late-stage pipeline, contributing to portfolio expansion and broadening its impact across multiple indications. Nimbus Lakshmi is a US-based company specializing in Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hereditary angioedema therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. he hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Angioedema Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary angioedema therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary angioedema therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary angioedema therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: C1 Esterase Inhibitor; Selective Bradykinin B2 Receptor Antagonist; Kallikrein Inhibitor; Other Drug Classes
• 2) By Route of Administration: Intravenous; Subcutaneous; Oral
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
• 4) By Application: Prophylaxis; On-demand
• Subsegments:
• 1) By C1 Esterase Inhibitor: Plasma-Derived; Recombinant
• 2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
• 3) By Kallikrein Inhibitor: Ecallantide; Lanadelumab
• 4) By Other Drug Classes: Emerging Therapies
• Companies Mentioned: Sanofi S.A.; Pharming Healthcare Inc.; Attune Pharmaceuticals Inc.; Adverum Biotechnologies Inc.; Arrowhead Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hereditary Angioedema Therapeutics Market Characteristics

3. Hereditary Angioedema Therapeutics Market Trends And Strategies

4. Hereditary Angioedema Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Hereditary Angioedema Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hereditary Angioedema Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hereditary Angioedema Therapeutics Market Growth Rate Analysis
• 5.4. Global Hereditary Angioedema Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hereditary Angioedema Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hereditary Angioedema Therapeutics Total Addressable Market (TAM)

6. Hereditary Angioedema Therapeutics Market Segmentation

• 6.1. Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• C1 Esterase Inhibitor
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Other Drug Classes
• 6.2. Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Oral
• 6.3. Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.4. Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prophylaxis
• On-demand
• 6.5. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasma-Derived
• Recombinant
• 6.6. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Icatibant
• 6.7. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ecallantide
• Lanadelumab
• 6.8. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Emerging Therapies

7. Hereditary Angioedema Therapeutics Market Regional And Country Analysis

• 7.1. Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Angioedema Therapeutics Market

• 8.1. Asia-Pacific Hereditary Angioedema Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Angioedema Therapeutics Market

• 9.1. China Hereditary Angioedema Therapeutics Market Overview
• 9.2. China Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Angioedema Therapeutics Market

• 10.1. India Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Angioedema Therapeutics Market

• 11.1. Japan Hereditary Angioedema Therapeutics Market Overview
• 11.2. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Angioedema Therapeutics Market

• 12.1. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Angioedema Therapeutics Market

• 13.1. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Angioedema Therapeutics Market

• 14.1. South Korea Hereditary Angioedema Therapeutics Market Overview
• 14.2. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Angioedema Therapeutics Market

• 15.1. Western Europe Hereditary Angioedema Therapeutics Market Overview
• 15.2. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Angioedema Therapeutics Market

• 16.1. UK Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Angioedema Therapeutics Market

• 17.1. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Angioedema Therapeutics Market

• 18.1. France Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Angioedema Therapeutics Market

• 19.1. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Angioedema Therapeutics Market

• 20.1. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Angioedema Therapeutics Market

• 21.1. Eastern Europe Hereditary Angioedema Therapeutics Market Overview
• 21.2. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Angioedema Therapeutics Market

• 22.1. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Angioedema Therapeutics Market

• 23.1. North America Hereditary Angioedema Therapeutics Market Overview
• 23.2. North America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Angioedema Therapeutics Market

• 24.1. USA Hereditary Angioedema Therapeutics Market Overview
• 24.2. USA Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Angioedema Therapeutics Market

• 25.1. Canada Hereditary Angioedema Therapeutics Market Overview
• 25.2. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Angioedema Therapeutics Market

• 26.1. South America Hereditary Angioedema Therapeutics Market Overview
• 26.2. South America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Angioedema Therapeutics Market

• 27.1. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Angioedema Therapeutics Market

• 28.1. Middle East Hereditary Angioedema Therapeutics Market Overview
• 28.2. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Angioedema Therapeutics Market

• 29.1. Africa Hereditary Angioedema Therapeutics Market Overview
• 29.2. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Angioedema Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Hereditary Angioedema Therapeutics Market Competitive Landscape
• 30.2. Hereditary Angioedema Therapeutics Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pharming Healthcare Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Attune Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Adverum Biotechnologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Angioedema Therapeutics Market Other Major And Innovative Companies

• 31.1. Ionis Pharmaceuticals Inc.
• 31.2. BioCryst Pharmaceuticals Inc.
• 31.3. CSL Behring LLC
• 31.4. KalVista Pharmaceutical Inc.
• 31.5. CENTOGENE N.V.
• 31.6. GlaxoSmithKline plc.
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. AbbVie Inc.
• 31.10. Incyte Corporation
• 31.11. BioMarin Pharmaceutical Inc.
• 31.12. Dyax Corp.
• 31.13. Salix Pharmaceuticals Inc.
• 31.14. Pharvaris N.V.
• 31.15. Innovent Biologics Inc.

32. Global Hereditary Angioedema Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market

34. Recent Developments In The Hereditary Angioedema Therapeutics Market

35. Hereditary Angioedema Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Hereditary Angioedema Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hereditary Angioedema Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hereditary Angioedema Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer